TW200621240A - Cancer treatments - Google Patents

Cancer treatments

Info

Publication number
TW200621240A
TW200621240A TW094138843A TW94138843A TW200621240A TW 200621240 A TW200621240 A TW 200621240A TW 094138843 A TW094138843 A TW 094138843A TW 94138843 A TW94138843 A TW 94138843A TW 200621240 A TW200621240 A TW 200621240A
Authority
TW
Taiwan
Prior art keywords
methods
cancer treatments
treatments
assessing
death
Prior art date
Application number
TW094138843A
Other languages
English (en)
Chinese (zh)
Inventor
Heather Helene Bendall
Gary T Elliott
Lorenzo M Leoni
Christina Carol Niemeyer
Pratik S Multani
Original Assignee
Salmedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200621240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salmedix Inc filed Critical Salmedix Inc
Publication of TW200621240A publication Critical patent/TW200621240A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW094138843A 2004-11-05 2005-11-04 Cancer treatments TW200621240A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
TW200621240A true TW200621240A (en) 2006-07-01

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138843A TW200621240A (en) 2004-11-05 2005-11-04 Cancer treatments

Country Status (12)

Country Link
US (2) US20060128777A1 (de)
EP (1) EP1814544A4 (de)
JP (1) JP2008519047A (de)
CN (1) CN101933923A (de)
AR (1) AR054094A1 (de)
AU (1) AU2005317047A1 (de)
CA (1) CA2585659A1 (de)
CL (1) CL2009001721A1 (de)
MX (1) MX2007005361A (de)
NO (1) NO20072654L (de)
TW (1) TW200621240A (de)
WO (1) WO2006065392A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1611088T3 (da) 2003-04-07 2009-10-19 Pharmacyclics Inc Hydroxymater som terapeutiske midler
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US8962614B2 (en) * 2008-04-17 2015-02-24 The Johns Hopkins University ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors
AU2009296734B2 (en) * 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
AU2009321745B2 (en) * 2008-12-03 2016-06-23 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010097700A1 (en) * 2009-02-25 2010-09-02 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2010126676A1 (en) * 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
PT2528602T (pt) * 2010-01-28 2017-01-12 Eagle Pharmaceuticals Inc Formulações de bendamustina
KR101830142B1 (ko) * 2010-06-02 2018-02-20 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 경구 투약 형태
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
KR20140064873A (ko) 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
CA2867343C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
CA2925922C (en) 2013-09-30 2023-03-21 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
EP3116481A1 (de) 2014-03-13 2017-01-18 Vasilios VOUDOURIS Feste bendamustin -dispersionen und dauerinfusion
ES2742197T7 (es) 2015-07-23 2021-10-06 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PT725642E (pt) * 1993-10-27 2000-05-31 Upjohn Co Prostaglandina e 1 estabilizada
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
EP1104297B8 (de) * 1998-07-09 2006-05-03 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002048141A1 (en) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
KR20040025881A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
CA2462723C (en) * 2001-10-15 2012-05-01 Hemoteq Gmbh Coated stents for preventing restenosis
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
PT1501565E (pt) * 2002-05-09 2007-02-28 Hemoteq Gmbh Compostos e processos para o revestimento hemocompatível de superfícies
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
WO2004074325A2 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
AU2005317047A1 (en) 2006-06-22
EP1814544A4 (de) 2009-12-02
WO2006065392A2 (en) 2006-06-22
US20060128777A1 (en) 2006-06-15
MX2007005361A (es) 2008-01-11
US20090209606A1 (en) 2009-08-20
AR054094A1 (es) 2007-06-06
NO20072654L (no) 2007-07-25
CA2585659A1 (en) 2006-06-22
WO2006065392A3 (en) 2006-12-21
JP2008519047A (ja) 2008-06-05
EP1814544A2 (de) 2007-08-08
WO2006065392A8 (en) 2007-03-01
CN101933923A (zh) 2011-01-05
CL2009001721A1 (es) 2010-02-19

Similar Documents

Publication Publication Date Title
TW200621240A (en) Cancer treatments
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2006081510A3 (en) Methods for treating renal cell carcinoma
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
RS20050802A (en) Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006099261A3 (en) Potent and specific immunoproteasome inhibitors
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
ATE510553T1 (de) Beta-2-glycoprotein 1 als angiogenesehemmer
WO2006096759A3 (en) Methods and compositions for treating cancer
WO2002102306A8 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity